Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Antara Mallampalli

Critical Care Medicine Tucson, AZ Medical Doctor

NPI 1992885396 CMS profile 534047

6567 E Carondelet Ste 215, Tucson, AZ 85710

Open in the dashboard

General payments

$2,009

97 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Antara Mallampalli of Tucson, AZ is reported in the CMS Open Payments database as having received $2,009 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $21 1
2022 General $803 31
2021 General $371 22
2020 General $222 15
2019 General $592 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antara Mallampalli
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Antara Mallampalli were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Antara Mallampalli Critical Care Medicine median Middle half National median
2019 $592 $149 $51–$535 $163
2020 $222 $110 $30–$325 $114
2021 $371 $125 $34–$403 $132
2022 $803 $157 $49–$582 $149
2023 $21 $162 $56–$621 $160
2024 $0 $168 $53–$634 $164
2025 $0 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $371 16 payments
  2. GlaxoSmithKline, LLC. $308 21 payments
  3. Intuitive Surgical, Inc. $289 2 payments
  4. Grifols USA, LLC $164 10 payments
  5. Jazz Pharmaceuticals Inc. $149 7 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $104 6 payments
  7. United Therapeutics Corporation $92 5 payments
  8. Genentech USA, Inc. $91 4 payments
  9. Merck Sharp & Dohme Corporation $81 6 payments
  10. Insmed, Inc. $78 3 payments
  11. Other $281 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,009 97 payments
Products named General payments · program years 2019–2023
  1. Da Vinci Surgical System $289 2 payments
  2. TRELEGY ELLIPTA $230 15 payments
  3. Prolastin-C Liquid $164 10 payments
  4. SYMBICORT $97 5 payments
  5. Esbriet $91 4 payments
  6. SPIRIVA RESPIMAT $87 5 payments
  7. XYWAV $85 4 payments
  8. Arikayce $78 3 payments
  9. TYVASO $74 4 payments
  10. ZERBAXA $69 5 payments
  11. Other $874 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record